Minsheng Securities released a research report on April 23 stating that it gave Shandong Pharmaceutical (600529.SH) a recommended rating. The main reasons for the rating include: 1) the company released the 2023 annual report & 2024 quarterly report; 2) the core product molded bottle & brown bottle grew rapidly; 3) abundant cash flow and completed profit commission and incentive extraction after meeting performance standards; 4) the high demand for borosilicate molded bottles continued to contribute to increased growth with overseas products; 5) refined management reduced costs and increased efficiency, and the 2024 soda price reduction released profit elasticity. (Mainichi Keizai Shimbun)
民生证券4月23日发布研报称，给予山东药玻（600529.SH）推荐评级。评级理由主要包括：1）公司发布2023年年报&2024年一季报；2）核心产品模制瓶&棕色瓶增长迅速；3）现金流充裕，业绩达标后完成利润提成和激励提取；4）中硼硅模制瓶需求高景气，与出海产品持续贡献增量；5）精细化管理降本增效，2024年纯碱降价释放盈利弹性。（每日经济新闻）
Minsheng Securities released a research report on April 23 stating that it gave Shandong Pharmaceutical (600529.SH) a recommended rating. The main reasons for the rating include: 1) the company released the 2023 annual report & 2024 quarterly report; 2) t
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.